Presented Results

News Articles for Presented Results top ^

2013/4/29

Oramed Pharmaceuticals to Present Results of its Key Clinical Studies of Oral Insulin in Type 1 Diabetes Patients at the GTC Diabetes Summit, Boston, MA; April 29-30, 2013

JERUSALEM , April 29, 2013 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (NASDAQCM: ORMP) ( http://www.oramed.com ), a developer of oral delivery systems of drugs currently administered by injection, announced today that its abstract, entitled "Oral insulin capsules toward management of Type 1 diabetes mellitus," will be presented at the Global Technology Community Diabetes Summit 2013.

View more Oramed Pharmaceuticals to Present Results of its Key Clinical Studies of Oral Insulin in Type 1 Diabetes Patients at the GTC Diabetes Summit, Boston, MA; April 29-30, 2013 analysis

Sign-up for Oramed Pharmaceuticals to Present Results of its Key Clinical Studies of Oral Insulin in Type 1 Diabetes Patients at the GTC Diabetes Summit, Boston, MA; April 29-30, 2013 investment picks

2013/3/11

Cardiovascular Systems Presents Results from Pivotal Coronary Trial at ACC

Cardiovascular Systems, Inc. (CSI) (Nasdaq: CSII) , presented pivotal 30-day data from its ORBIT II study of severely calcified coronary lesions at the 2013 American College of Cardiology (ACC) conference in San Francisco.

View more Cardiovascular Systems Presents Results from Pivotal Coronary Trial at ACC analysis

Sign-up for Cardiovascular Systems Presents Results from Pivotal Coronary Trial at ACC investment picks

2013/2/19

Ituran Location and Control Ltd. Presents Results for the Fourth Quarter and Full Year 2012

Full Year Revenues of $150 million and EPS of $1.19 AZOUR, Israel , February 19, 2013 /PRNewswire/ -- Ituran Location and Control Ltd.

View more Ituran Location and Control Ltd. Presents Results for the Fourth Quarter and Full Year 2012 analysis

Sign-up for Ituran Location and Control Ltd. Presents Results for the Fourth Quarter and Full Year 2012 investment picks

2013/5/13

Ituran Location And Control Ltd. Presents Results For The First Quarter 2013

Revenues of $41 million and EPS of $0.29 AZOUR, Israel , May 13, 2013 /PRNewswire/ -- Ituran Location and Control Ltd.

View more Ituran Location And Control Ltd. Presents Results For The First Quarter 2013 analysis

Sign-up for Ituran Location And Control Ltd. Presents Results For The First Quarter 2013 investment picks

2013/6/3

AbbVie Presents Results from Phase I Study of Investigational Oncology Compound ABT-199 at American Society of Clinical Oncology Annual Meeting

Data in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia and Non-Hodgkin's Lymphoma Enrollment in Clinical Trials for ABT-199 Continues NORTH CHICAGO, Ill.

View more AbbVie Presents Results from Phase I Study of Investigational Oncology Compound ABT-199 at American Society of Clinical Oncology Annual Meeting analysis

Sign-up for AbbVie Presents Results from Phase I Study of Investigational Oncology Compound ABT-199 at American Society of Clinical Oncology Annual Meeting investment picks

2013/6/3

NewLink Genetics Presents Results from Two Phase 1 Studies with Immunotherapy Agent, Indoximod, at the ASCO 2013 Annual Meeting

Data Demonstrate Evidence of Indoximod's Safety and Anti-Tumor Activity When Used in Combination with Other Anti-Cancer Agents in Metastatic Solid Tumors AMES, Iowa , June 3, 2013 /PRNewswire/ -- NewLink Genetics Corporation (NASDAQ: NLNK) , an oncology-focused biopharmaceutical company specializing in immunotherapy, today announced results from two clinical studies with indoximod, an orally administered small molecule drug candidate that inhibits the IDO pathway.

View more NewLink Genetics Presents Results from Two Phase 1 Studies with Immunotherapy Agent, Indoximod, at the ASCO 2013 Annual Meeting analysis

Sign-up for NewLink Genetics Presents Results from Two Phase 1 Studies with Immunotherapy Agent, Indoximod, at the ASCO 2013 Annual Meeting investment picks

Start Premium Trial

P	F	Fund Financial Data (13,000+ funds)
P	F	Stock Financial Data (7,000+ stocks)
P	F	Stock and Fund Screeners (basic)
P	F	Investing Articles and Market Commentary
P	F	Articles Archive (>30 days)
P	F	Discuss (dozens of stock, fund, bond, and general bulletin boards)
P	F	Portfolio Manager (basic)
P	F	Morningstar Investment Classroom
P	F	Morningstar Investing Classroom Rewards (earn as you learn and redeem for Morningstar merchandise)
P		Morningstar Fund Analyst Reports (full research on 2,000 funds and ETFs)
P		Morningstar Stock Analyst Reports (full research on 2,000 stocks)
P		Morningstar Stock and Fund Stewardship Grades
P		Portfolio Manager (advanced with 10 x-ray analyses, including guidance)
P		Portfolio Monitor (monthly and on-demand personalized portfolio statements)
P		Morningstar Proprietary Stock Information (stock star ratings, buy/sell prices, economic moat ratings, and more)
P		Morningstar Stock and Fund Favorites & Red Flags eNewsletters
P		Premium Stock and Fund Screeners (advanced with nearly infinite ways to find the best securities for you)
P		Discounts on Morningstar newsletters, books, seminars, and more

Sign-up to Morningstar

Basic Access

Articles and Videos
Morningstar video reports, articles, data, and tools. Dig into our lineup of e-newsletters and investing classroom courses outlining sensible strategies for maximizing your investments.

Morningstar Discuss
Follow the buzz on individual stocks or fund families. Plus, read the latest posts from Morningstar members and analysts.

Portfolio Manager
Track your investments and watch lists with our Portfolio Manager. Customize your view with our comprehensive stock, fund, and ETF data.

Access these features and more when you sign up for Free Membership.
Join Morningstar today. It's Free.

Unlimited Access

Analyst Research
Gather in-depth, actionable insight on over 3,700 stock and mutual funds covered by Morningstar analysts. View our mutual fund Analyst Reports favored by professionals, savvy experienced investors, and new investors researching options for retirement savings, college plans, or other investment needs.

Portfolio X-Ray®
Ensure your portfolio is positioned exactly how you want with Morningstar's X-Ray Interpreter and Stock Intersection tools. A Barron's "Best of the Web" award winner for five years running, X-Ray Interpreter goes under the hood of your portfolio to provide a useful allocation, sector, and geographic analysis. And you can discover how much of a stock you really own, individually and through mutual funds, with Stock Intersection.

Investment Picks
Find new 5-star stocks (greatly undervalued companies) to consider daily. Our 5-star stock rating is a proven winner, consistently beating benchmarks like the S&P 500. Plus, browse our Fund Analyst Picks and Stewardship Grades to find shareholder-friendly mutual funds that are poised for outperformance.

Portfolio Monitor
Get a clear view of your investments with personalized reports about your portfolio. Receive monthly statements and generate reports on-demand to help you stay on track to meet your investment goals.

Access these features and more when you sign up for Premium Membership.
Start your free 14-day trial today online
Your subscription may be tax deductible. Please contact your tax advisor.

Site Directory Site Map Our Products

Corrections Help Advertising Opportunities Licensing Opportunities Glossary RSS Mobile Portfolio Affiliate Careers Company News

Presented Results

Stocks by:

Mutual Funds by:

ETFs by:

Articles by:

Premimum Stocks by:

Premimum Funds by:

Premimum ETFs by:

Star Rating | Category | Total Assets | Symbol / Ticker | Name